There is more misinformation about tirzepatide than almost any compound discussed online right now.
Let’s fix that with actual trial data.
The pace of research on this compound is accelerating faster than anything I’ve seen in fitness and longevity.
Recently, I’ve put more time into researching GLP-1s than almost anything else over the last few years.
What I found changed how I think about longevity.
Most of what I’m about to share was published in the last few months, late 2025 into early 2026.
We are genuinely in the early innings of understanding how powerful this thing is.
Let’s walk through the main findings.
1. For cardiovascular health alone, the case is already overwhelming.
Real-world data across 118,000 patients[1] showed tirzepatide REDUCED risk of heart attack by 26%, heart failure by 35%, stroke by 29%, and all-cause mortality by 51%.
In SURMOUNT-5, it reduced predicted 10-year cardiovascular disease risk nearly twice as much as semaglutide.
This is one of the most compelling longevity arguments for any compound available.
Most people think of tirzepatide as only a weight loss drug.
It’s so much more than that.
2. Tirzepatide is now being looked at as a longevity compound.
Even in already lean people, tirzepatide improves insulin sensitivity, glucose uptake into muscle, glycogen storage, and blood lipids.
My own HbA1c dropped from 5.5 to 4.8.
That’s deep metabolic optimization.
This is why my personal interest in tirzepatide is at low doses… the metabolic and longevity application, not just rapid weight loss.
3. It also doesn’t suppress baseline dopamine.
Tirzepatide modulates dopamine response to specific compulsive reward stimuli.
- Overeating
- Alcohol
- Gambling
Baseline dopamine, motivation, drive, and emotional capacity are untouched.
The clinical trials[2] confirmed no depression signal, no anhedonia, no motivational impairment.
4. No increase in cancer.
For thyroid cancer: The black box warning is from rat studies.
Human thyroid cells have far fewer GLP-1 receptors than rat thyroid cells. The biology doesn’t translate.
In a real-world study[3] of 283,000 humans, tirzepatide users actually showed significantly LOWER thyroid cancer incidence.
Zero cases of medullary thyroid carcinoma were reported across all 13 RCTs.
Pancreatic cancer? No issue.
A meta-analysis[4] of 13 randomized controlled trials covering nearly 14,000 participants showed identical cancer risk between tirzepatide and control groups across every cancer type, including pancreatic.
5. Bone loss and gallstones are tied to rapid weight loss, not tirzepatide.
Rapid weight loss can reduce bone density if not managed correctly. This is not unique to tirzepatide. It applies to any significant caloric deficit over an extended period.
Resistance training is the single most powerful stimulus for maintaining bone density.
And for the majority of people, gallstones are not an issue.
Rapid weight loss of any kind (surgery, aggressive dieting, or Tirz) can add to that
This is really a concern for people who are obese and losing large amounts of weight quickly. For lean or moderately overweight people on a conservative dose, it’s much less of a relevant concern.
6. The actual side effects.
GI effects are dose-dependent, peak in the first 8 weeks, and resolve in over 95% of users by week 12.
With a low dose and slow titration, they’re minimal or non-existent.
The bottom line: The fear around tirzepatide is driven by rat studies and social media garbage.
The actual human trial data tells a completely different story.
Used correctly, at the right dose, this is one of the most positively impactful therapeutic compounds available.
If you want the proper setup, get started at Kino Clinic.
*Use this code at checkout to get $50 off your first order: gregory50
Low-dose tirzepatide, compounded by a licensed pharmacist. $179 a month.
Fill out a quick online form, a licensed physician reviews it, and if approved, your medication arrives within 3-5 business days.
No hidden fees.
For a limited time, get $50 off your first order.
Use this code at checkout: gregory50
Talk soon,
Greg O’Gallagher